

THE LIVED GENOME

Christoph Rehmann-Sutter and Dana Mahr

Introduction

FROM A MEDICAL perspective, the genome can today be used primarily as a source of health information for diagnoses and prospective disease risk management. Gene therapy may be an option in the future. For scientists, the genome is the sum of an organism's DNA molecules, which can be sequenced and used to explain heredity and development. What is a genome for those who have it in their bodies and who *live* it? How do they make sense of it? What meanings are associated with the genome in their lifeworlds, where identities are formed and decisions taken in personal, family and cultural contexts? It is a matter of perspectives. We all live a genome, but the questions that arise from people who *live* a genome are different from those raised by doctors and scientists who look at the genome as a functional part of cells. From the perspective of their own embodiment, people act as interpreters of their own 'lived' genome, of both its knowns and its unknowns.

Studying these acts of interpretation is an emerging area within the interdisciplinary field of medical humanities, combining qualitative research approaches, empirical ethics, philosophy and cultural studies. Lay people are considered experts in their lifeworlds and they are 'moral pioneers', as anthropologist Rayna Rapp¹ has put it in her study of the moral dilemmas of prenatal testing. In a broader sense, they are pioneers of sense-making in the course of a geneticisation of body knowledge.

We can specify two levels of questions that need to be raised in studies of the lived genome. The first of these relates to how information about genes and mutations affects the self and the identity of individuals and families: for instance, those with monogenic conditions such as hereditary cancer risks, Huntington's disease or cystic fibrosis. How do people communicate genetic risks to each other? How do they decide whether or not to know their genetic status? How do they narrate predictive genetics in regard to a specific condition?² How do they individualise the probabilities? The second level is the framework of more general genomic information, which is developed in genomic medicine and biology. This provides background concepts for interpreting what becomes accessible individually through personal genome scans based on single nucleotide polymorphisms (SNP),³ or whole-genome sequencing.

The complex functions of the genome are investigated by molecular biology and genetic medicine. It is a part of our bodies – a part of which humans were ignorant

before the advent of modern genetics. Being invisible and insensible (other than arms, legs or muscles), the genome is not part of what phenomenologists have described as the *body schema*, through which we know about the relative position of each of our limbs.⁴ But nevertheless it is creatively imagined and integrated into a culturally and individually negotiated and narrated corporeal identity, within diverse local accounts of intersubjective relatedness. According to the distinction between body schema and body image discussed by Shaun Gallagher,⁵ the genome can, however, be part of the *body image*, which is a conscious representation of the body. As such it is part of the knowledge resources in the lifeworld. By systematically exploring the lifeworld from a first-person perspective of those living and shaping it, and by focusing on practices of personal meaning-making, phenomenology and qualitative research, we can approach the question of what a genome *is* by asking: What does it mean to live as somebody with this genome?

In the first section of this chapter we introduce a theoretical perspective by distinguishing between two perspectives on the genome, the 'biomedical genome' and the 'lived genome'. We also introduce the way in which we are mobilising the concept of the 'lifeworld' in the context of our research. The genome is something peculiar if conceived from a first-person perspective. Those living a genome do not only *have* it and obtain the information about the body they *are*, but also they *do* many things in order to make sense of their genome. Interpretative work is being done in social and practical contexts; we propose speaking of 'reflexive embodiment'. Reflexive embodiment is an active process, rather than something in which people are just 'affected' by the implications of genomics. The second section is dedicated to the guiding questions and methods for investigating this lived genome and the social epistemology of genomics. In our final section we discuss examples from a study on Crohn's disease and ulcerative colitis, both inflammatory bowel diseases. These conditions were selected because, while they have been treated as paradigmatic 'psychosomatic' diseases, genetic factors have recently been found to be involved and these findings are currently transforming the medical understanding of the disease aetiology. The 'geneticisation' of these diseases can be observed in real time, affecting both medical practice and disease experience.

Two 'Genomes'

Actively and passively, more and more people are taking part in cultures of genetic knowledge.⁶ On many levels, they are immersed and involved in communication about genetics. People in industrialised countries are increasingly encouraged to make decisions about predictive or diagnostic genetic tests when starting a family; before,⁷ during and after pregnancy; and before, during and after illness. Medicalisation is followed by geneticisation. Foetal DNA can now be tested non-invasively and with minimal risk to the pregnancy through a few drops of mother's blood, with the result that more pregnancies may be turned into 'risk pregnancies'.⁸ More and more tests are included in newborn screening. The cost of a complete personal genome sequence has been



tumbling; currently, it has fallen below the magic sum of USD 1000. Large biobanks and information repositories have been established, such as the UK Biobank, which holds data on more than half a million patients, or the 100,000 Genomes Project, constituting unique research infrastructures. The media provide ample (selective and always interpreted) information about the latest breakthroughs in genomic research. Increasingly large parts of whole patient populations are transformed into genomic study samples followed by systems medicine (see also William Viney's chapter in this volume).⁹ The omnipresence of available genetic knowledge has changed the cultural 'frames' for disease, health and responsibility, and new private and public duties seem to emerge: a possible duty of the individual to know his or her own genes¹⁰ and a possible duty of healthcare professionals to tell people about their genetic risks.¹¹

Much has been written about potential changes in self-image, body schema, and the possible implications of genetic risks for individual visions of future life.¹² Now new, further questions concern the meanings of genomic knowledge for those who have to deal with it and integrate it, transform and translate it into their everyday lives. We need a better understanding, as Barbara Prainsack and Jenny Reardon have put it, of how

whole-genome information is used by, and what it means to, a wide range of users. . . . An understanding of what a broader range of users hope to learn from this type of whole-genome information, and whether it would lead to actual life and behaviour changes, would help in assessing whether personal genomics services are likely to be adopted in large numbers.¹³

This knowledge about the users' (and non-users') hopes, fears and subjective understandings with regard to genetic knowledge must be based on an adequate kind of evidence. Such evidence would be needed for planning the good governance of genomics. Questions such as: 'What does my genetic make-up mean for myself and for my family?' or: 'In what sense "am I my genes"?'¹⁴ should therefore be occasions not only for theoretical speculation but also for empirical research, applying qualitative, hermeneutic and phenomenological methodologies. We need to study the ongoing 'reflexive embodiment'¹⁵ of genetic knowledge.

In the first place, we need a theoretical framework that can integrate these processes of individual translation and management of genetic information and its integration into personal lives. By explaining the genome as something that is not only investigated and used in biomedical contexts but also 'lived' individually, in families and in societies, we hope to contribute to such a framework.

The reflexively embodied genome is thus charged with basically two sets of meanings that both differ and interact. One is the set of meanings that are attached to the genetic in biomedical research and in clinical contexts. For the sake of simplicity, we call this perspective, and what is seen in it, 'genome 1'. The genome, however, is translated and transformed into a related but dramatically different figuration that we call here 'genome 2', which is the genome seen within the lifeworlds of the individuals concerned.



Scientists who are socialised into the frames of genome 1 may think that their genome is the only true one, while the people's view of the genome is just a subjective translation. They may find many elements of genome 2 (in lay people's understandings) imprecise, even incorrect. Their view of 'reality' is the sober world of mathematical models, of physics and chemistry, and of the complex charts of cellular systems with which they work. However, some users of genomic knowledge (other than scientists and healthcare professionals, who may themselves be personal users of genomic information) may equally well find genome 1 too abstract and lacking clear sense for the practical decisions they need to make.

We do not think that either genome 1 or genome 2 is necessarily simpler but rather that they are related to different complexities. Similarly, we do not think that either genome 1 or genome 2 is wrong or biased, but that they have different truth criteria. Furthermore, genome 1 is not only the raw material for a simplification, or application into genome 2. Both are valuable, and their inter-relation is interesting to study. Both are concrete for people, and both are in some way necessary; however, they carry different phenomenological features of concreteness. The process of reflexive embodiment can hence be seen as an activity of mutual translations between different meaning contexts.

A linear 'deficit' model of the popularisation of scientific knowledge from medical experts to patients, which had been assumed for decades, has become largely obsolete within Science and Technology Studies.¹⁶ It is certainly not helpful for elucidating the process of reflexive embodiment of genetic knowledge. Both sides have advantages and deficits, and both sides need to tell each other what they know and how they know it, how their knowledge produces evidence. A deficit model does not allow the user perspective to be taken as seriously as the provider perspective, since users are considered to be at the receiving end of the communication cascades. We prefer a model that assumes active contributions from both sides. The terminological symmetry between 'genome 1' and 'genome 2' should signify this. Meaning-making in the field of genetics and genomics is a joint enterprise between producers and users of genetic knowledge, between science and society. The meanings on the two sides, however intertwined, differ considerably – and sometimes they clash.

In the course of research and also in clinical practice, situations are currently emerging where people typically need to decide about seeing large parts of their own genomic information. Genetic counselling normally deals with the complexities of genetic information about individual diseases or impairments. Decisions now need to be taken about knowing a whole genome, an exome, or a wide range of SNPs. The people concerned cannot know about all the conditions about which they will potentially acquire predictive information; too-long lists of diseases may potentially be included. Such situations seriously challenge the capacity for voluntary decision-making about the disclosure of information. This is not unique but intrinsically related to whole-genome studies: too many heterogeneous possibilities that are virtually impossible to grasp, and therefore an impossible mission for genetic counselling. The meaning of potential knowledge (in both the genome 1 and 2 perspectives) is

tightly bound to the concrete conditions. Genetic risks for breast cancer pose different questions for decision-making than the risk for macular degeneration or for Alzheimer's.¹⁷ The whole genome, as an object for informed decision-making about comprehensive disclosure, is therefore a moral conundrum. Decisions are virtually impossible to take 'consciously', in the classical sense of properly understanding all relevant implications of a decision.¹⁸ In order to make better-informed decisions, ideally, decision-makers would need to understand the lifeworld meaning of the genetics of each of the conditions potentially covered by testing. If somebody is uneasy about an a priori decision, desires to be as informed as possible about all risks to health, and asks for more detailed knowledge, then this would need to include both genome 1 and 2 perspectives on all conditions possibly involved.

While genome 1 is actually studied condition by condition – this is the aim of all big research programmes in current systems medicine, genome 2 knowledge is not yet gathered systematically. A similarly progressive condition-by-condition analysis of genome 2 would be needed.

Reflexive embodiment is a basic human capability, connecting the individual and the social. As social philosophers Margaret Archer and Nick Crossley explain, it is undertaken through dialogues, internal conversations and conversations with others.¹⁹ The individual person is always woven into social contexts and their self-image can be perpetually reconfigured. The question of what we 'embody' is in the foreground here. The body has inherited older key terms of existence. Issues of genetics are issues of corporeality.²⁰ We can ask: How and on what levels do we internalise, process and reflect the highly complex and partially uncertain knowledge about our own genome when it is disclosed to us (and potentially to others) and interpreted by geneticists? How do we translate their interpretations into our own identities, into lifeworlds, when we, as culturally and socially embedded people, are confronted, so to speak, with our biochemical self? A special feature of genomic knowledge is that it is about our bodies and our selves. By definition, it has anthropological significance,²¹ but this significance is not explicitly contained in the content of biomedical information. In order to understand this anthropological significance, we need to explore and 'decode' genome 2 as well.

The first human genome sequence was completed by 2003 and, perhaps paradoxically, during the same historical period the biological role of the genome was contested and reinterpreted. The semantic transformations that took place for genome 1 are also important for genome 2. To give a brief background, the old conception of the genome as a 'genetic program' was devised by eminent biologists around 1960,²² long before research in developmental molecular genetics had begun and details of the developmental functioning of genes were discovered. However, in the context of systems biology, the genetic program view has lost its theoretical plausibility, while still being socially active in the context of the genome 2. It has now been replaced or complemented by a family of less gene-centric, deterministic and essentialist images, such as a molecular orchestra of the cell, whose music (the life of the cell) is produced by an interplay of diverse components, of which the genome is one part; or

a library, whose actualised information content depends on those who use it by checking out and creatively reading a selection of books.²³ Hence, the biomedical significance of the genome, while being significantly expanded, is also undergoing critical transformation.

We suggest using and developing ‘genome 1’ – the biomedical genome – and ‘genome 2’ – the lived genome – analytically, as two hermeneutic perspectives. They represent two different but inter-related interpretative contexts of the genome, and at the same time two different levels of interpretation. Genome 2 is seen in lifeworld contexts by those who know the biopsychosocial implications of genetic susceptibilities and diseases at first hand: that is, by people ‘living’ a condition, having had or not having had a test, being directly involved as a patient or indirectly by being a member of an affected family. Healthcare professionals are also (in part) concerned with genome 2. In their professional work, which combines the biomedical and the patient-centred views, they cross the interface between the two perspectives. Genome 1 contains all testable genetic variations, SNPs, sequences and genomic data, together with the corresponding medical interpretation given by doctors, scientists and genetic counsellors. It includes explanations of genetic risks, of inheritable factors and so on, and explanations of the functioning of the genome and its variations in the cellular metabolism. Genome 2 is the genome in the understanding of those who embody the genome, who ‘live’ it, who are affected by it, who narrate it and understand their relationships to others by using elements of genetic knowledge, who make life plans accordingly (choosing a partner, planning a family and so on). The genome is imagined and continuously reconceptualised in the lifeworld of those individuals and families who live the genome. This lived genome interprets²⁴ the biomedical construct of a physico-chemical entity that is called a ‘genome’, which – in contrast to other parts of the body such as the beating heart – is not accessible to direct experience. It thereby integrates culturally mediated symbols and metaphors of genetics (such as the genome as a ‘language’, a ‘text’, a ‘program’, a ‘library’, a ‘mosaic’ and the like) and combines them with personal understandings into a partially comprehensible and partially mysterious text.

Edmund Husserl introduced the term ‘lifeworld’ in *The Crisis of European Sciences and Transcendental Phenomenology* (1936).²⁵ The lifeworld is prior to the objective knowledge of the physical sciences, and works as a collective intersubjective pool of perceiving. It acts as a foundation for the scientific perception of reality, in which an idealised (mathematically abstract) ‘nature’ of scientific theory, in the perception of members of society, replaces the pre-scientific and concrete lifeworld. As Husserl claimed, this process of substitution of the mathematically sub-structured world of physics for the real world started historically with Galileo, who successfully invented the method of geometrical idealisation in physical research and believed, as he famously put it, that the book of nature is written in mathematical language – which is an ontological claim. This concept of the lifeworld as a pre-scientific world was then expanded and developed by sociologists of knowledge such as Alfred Schütz and Thomas Luckmann.²⁶ They speak of reserves of knowledge that have certain structures



and are composed of different types of knowledge with different levels of relevance. In order to make this concept useful for a social epistemology of genetic knowledge, we suggest that the lifeworld needs to be understood in such a way that it can incorporate scientific knowledge as well, although in an interpreted form. That is what we mean when we speak of the genome 1 and genome 2 as 'inter-related'. Scientific knowledge is not incorporated into genome 2 in its 'raw' form, as produced by science and medicine. It is transformed in order to meet the needs of everyday life. *How* this translation is performed is an empirical question that is interesting to explore regarding specific topics – such as genomics. In order to learn about that, we need to ask the people who do this translation, since they are experts on their lifeworld genetic knowledge.²⁷ This investigation needs to be sensitive to a transformation of the 'gaze', which is implied in the geneticisation of disease experiences. The gaze of the Galilean type²⁸ sees the limits on embodied human existence as issues for technical improvement, for the management of risks and the maximisation of wellbeing, while a lifeworld 'gaze' would include a broader repertoire of meanings.

Research Perspectives: Methods for Studying the Lived Genome

In order to study the lived genome we need to look at the processes by which people make sense of genomic information in lifeworld contexts. Geneticisation, a term introduced by Lippman in 1991, 'refers to an ongoing process by which differences between individuals are reduced to the DNA codes, with most disorders, behaviours and physiological variations defined, at least in part, as genetic in origin'.²⁹ Applying this to the study of genome 2 would mean monitoring which differences between individuals are actually redefined as genetic, which aspects are lost by this reduction, and to what degree these variations are geneticised.

However, in order to understand the ways in which genetic explanations are also seen as positively *meaningful*, we need to expand the concept of geneticisation. Instead of expecting genetic explanations to be reductionist in the first place, involving a loss of value and meaning, we first ask which questions are answered by genetic explanations. To what question does genetic information provide an answer? What are the hopes and fears that people direct towards genetic explanations, even before they know them? A lived genome studies poses questions such as: What kind of evidence is produced by particular genetic explanations? In which context? By whom and for whom? What questions are hidden or silenced in social processes of 'genetic reduction'? What are the benefits of a genetic explanation of a condition? And what are the losses? How are genetic explanations creatively integrated into or complemented by non-genetic explanations?

These questions inspire the guiding research perspective of qualitative empirical studies in different ways. Here are a few examples. Monica Konrad³⁰ asked what it actually means to be classified as a person with a predisposition (specifically, to Huntington's disease), which local moralities guide the resolution of disclosure dilemmas, and how the life sciences create 'pre-symptomatic persons' as new forms of social



identities. Scully, Porz and Rehmann-Sutter³¹ asked how time functions as a factor in genetic decision-making. Britta Pelters³² organised her study of breast cancer patients ‘doing health’ around the question of how genetic diseases are socialised and what roles the disease adopts in families. Martin Richards³³ made an autobiographical ethnography describing his use of personal genome scans from two direct-to-consumer test companies. Robert Klitzman³⁴ took a comparative approach and studied the testing and disclosure decisions of symptomatic and non-symptomatic individuals with genetic predispositions for Huntington’s disease, alpha-1 antitrypsin deficiency and breast cancer. Andrea zur Nieden,³⁵ in her recent study of the subjectification of breast cancer, took an approach via narrative identity, asking how the interviewees position themselves in the discourse as a particular type of personality.

Since meanings need to be explored openly and testable hypotheses are rare, qualitative approaches are the methods of choice for studying the lived genome. Genes carry meanings within the lifeworlds of persons who experience the biological, psychological and social implications of genetic diseases – whether as affected individuals, family members, scientists or health professionals. These meanings need to be captured and understood. In narratives (which can be collected in interviews, focus groups, participant observation or documents) the intricacies of individual meaning-making and the individual interpretation of genomic knowledge (and other omics data) can be explored in depth. By observing situations of communication we can explore how different explanations and coping approaches interact with each other. Breaks can occur within and between individual epistemologies; tensions are to be expected where new understanding emerges. A lived genome study should centre on the views and experiences of individuals, compare their local sense-making strategies with those of others, and analyse both the narratives and (if a study includes focus groups or participant observations) the interactions.

For the interpretation of the data inductive research strategies can be used, such as Grounded Theory (GT)³⁶ or Interpretative Phenomenological Analysis (IPA).³⁷ The IPA perspective sensitises the researcher to the double hermeneutics of data analysis: the participants are searching for sense within their own experiences of life with a genetic disease or with the results of a genetic test, and in turn, the researcher is searching for sense within the narrated and transcribed sense-making strategies of the participants.³⁸ The researcher must reflect upon his or her preconceptions and pre-understandings of the data and the topics covered.³⁹ The interpreter should try to adjust his or her own preconceptions as part of the hermeneutical process.⁴⁰ This methodology is not meant to be exclusive; it can be complemented by methods from cultural studies, history, literary analysis or philosophical phenomenology.

Workshop: Embodiment and Socialisation of Genetics of Chronic Inflammatory Bowel Diseases

We are currently investigating the lived genome in a project about people living with chronic inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, in Germany.⁴¹ Within our understanding of the aetiology of these diseases there is a shift

taking place – from a psychosomatic paradigm to one of genetic susceptibility. Our working hypothesis is that this ongoing ‘geneticisation’ has practical significance in patients’ and their families’ lives, and that it is possible to investigate how the patients embody, socialise and reshape genetic knowledge in their own ways.

There are currently sixty-nine persons participating in our study. The sample is spread over all regions of Germany and all sectors of society. It includes thirty-seven cases of Crohn’s disease, fourteen cases of ulcerative colitis and eighteen relatives and friends of affected persons. The majority of the participants are women who are suffering from one of the two diseases. Most of the participating men are spouses or close friends.⁴² We have conducted forty semi-structured narrative interviews with patients and members of their families. Most of our study participants were recruited through a self-help organisation, the German Crohn’s/Ulcerative Colitis Association (Deutsche Morbus Crohn/Colitis ulcerosa Vereinigung (DCCV)). They were interviewed by the second author of this chapter. The interviews were recorded and transcribed verbatim. Pseudonyms were chosen by the researchers. In the course of the interviews, we invite the participants to talk freely about their life history with respect to their disease. This helps us to obtain an insight into their own understanding of their lifeworlds and their experiences with their diseases. These narratives already contain independent interpretations, pictures of and attitudes towards genetics and heredity that are deeply intertwined with life circumstances in both individual and social terms. As soon as this background is deployed, we invite the participants to talk about their attitudes, expectations and individual experiences of the genetic explanation of Crohn’s or colitis.

As described above, we use a mixed methodology for the analysis of the obtained material: an alloy of GT strategies and IPA. This mixture helps us to analyse the sense-making processes of our interlocutors within the rich context of their experiential worlds. We search for recurring patterns on the level of the narratives and compare them to those of other participants. Unlike Robert Klitzman, Andrea zur Nieden, Britta Pelters or even Monica Konrad, we try to avoid an early psychologisation in this process, and take our material seriously on the structural and narrative level. This kind of analysis has revealed two basic narratives of coping with the (partially conflicting) genetic and psychosomatic explanations of the disease: a narrative that centres on guilt and shame, and a narrative that centres on individual agency. Below, we sketch out and illustrate them with some translated quotations from interviews.

Narrative 1: Guilt

A first kind of narrative given by participants oscillated around experiencing guilt. Both patients and relatives described guilt as a constantly present and sometimes overwhelming emotion. Crohn’s or colitis, which sometimes causes ‘terrible, debilitating diarrhoea’,⁴³ can severely affect everyday family life. Especially during sporadic exacerbations, in phases of adverse food reactions or in the context of a progression of the disease, many things become extremely difficult or almost impossible to plan: periods abroad for study or holidays, dinners with friends, birthday celebrations, professional appointments or even visits to the hairdresser. For our participants,

these issues were often associated with apologies, remorse and the implicit sense of disappointing somebody.⁴⁴ Ulrike, a 45-year-old reiki master, reported that she sometimes felt guilty about poorly schedulable events – particularly in connection with her adult daughter:⁴⁵

I was off on a reiki weekend with her – something we've done together for years – and I had eaten salad two days in a row. What I did not realise was that it was just the moment where I could not take it, and the scars in my gut worsened the situation. That means for a start that it was all closed off. And then I threw up all night, and I recognised it and saw the signs [. . .]. [T]hen I thought: 'That poor girl, now she's here alone with me, there's no one else here to support her either.' That was a situation where I realised, very, very intensely, what a disease like this means or could mean for my children as well [. . .].⁴⁶

Here, guilt is also felt because of the possibility that her daughter has inherited susceptibility to the disease.

A second significant dimension of guilt is often imposed from the social environment and is verbalised as some kinds of accusation. Relatives, friends, colleagues, partners and sometimes even family doctors tell the patients that they are exaggerating their condition, they should pull themselves together, or give themselves a treat to overcome phases of disease. In the eyes of many of our interview partners, such statements imply that they are not making enough effort to improve their condition, that they are using their illness to evade responsibility or exaggerate at least parts of their condition.⁴⁷ The disease experience is interpreted as a mental health issue.⁴⁸

Many interviewees associate these negative reactions in the social environment with psychosomatic explanatory models. These models are thus perceived rather negatively, whereas other explanations such as a genetic aetiology are perceived as a relief. In the words of 46-year-old Ute from Karlsruhe:

I did understand that there is this argument that there is a barrier defect [a microbiomic explanation of chronic inflammatory bowel diseases, which is compatible with genetic explanations], and I found this a very great relief, and I said: 'Look, this explains my rheumatism as well. That simply explains the whole situation [. . .].'⁴⁹

And for me that was for a start a very great relief and an unburdening, because it is an incredible psychological pressure when you have the feeling that it's somehow your fault, I mean, if you put it on a psychosomatic track.⁴⁹

Even the saying 'a healthy mind in a healthy body', which is used in everyday life as well as in theories of illness, is hurtful in this context because it can be contradicted by lived experience. For example, Mechthild, a woman in her late fifties, who is involved in various self-help networks, states:

When I was a representative [of the DCCV] and doctors tried to show [other patients] that if they treat it properly they'll be as well as I am, then I always



objected vehemently and said: 'I think you're blaming us if you use me as a positive example, because I know many [other patients] who would like to live as well as I do, and I experience them as life-affirming as well. I mean, they're similar to me but they're still very ill.' So I've always been very much against it, if they tried to push us into this 'all-in-the-mind category', because I felt they [the doctors] wanted to abdicate responsibility, I mean, they didn't want to refer us to gastroenterologists as helpers, but to the psycho-people [psychotherapists].⁵⁰

The participant speaks about experiencing the way that health and personal attitude are often brought into a reciprocal confirmation context, by medical professionals – and she was used for this purpose in her function as the representative of a patient organisation. Her observation emphasised, however, that people can have severe diseases despite having a similarly positive attitude as she herself did. This made her resistant to such causal explanations based on a psychosomatic model because she recognised it as a practice of blaming patients for their condition. Moreover, she interprets the references to psychosomatics and the corresponding therapies as a way for physicians to avoid responsibility. Central to these statements is Mechthild's perception of psychosomatic medicine as something that transfers the blame for the disease to the patient – which is challenged by her everyday experience. Such positions arise frequently in the broad and prolonged experience of chronic inflammatory bowel diseases.

Patients may become a part of the medical history of their own diseases – as some of the participants told us. Personal biographical experiences and epistemologies can connect and combine so that they turn into medical explanatory models. One example of this is the story of the 65-year-old retiree, Agathe. She first suffered from severe diarrhoea and cramps in the 1970s. After a few weeks she consulted her family doctor and was diagnosed with ulcerative colitis – considered a psychosomatic disease within the prevailing medical paradigm of that time.⁵¹ The doctor told her, as she recollects, to 'have some psychotherapy to feel healthy again soon'.⁵² But that did not work well and her psychotherapist sent her for further diagnoses to Lübeck – then a leading location for psychosomatic research on chronic inflammatory bowel diseases. There, she gained more experience of the psychosomatic model and was given encouragement within that framework. Although the psychosomatic explanation worked well in therapy, it was repeatedly used by 'the outside' (i.e. her social environment) as some kind of 'my-fault theory'.⁵³ She felt the rise of genetic explanations in the 2000s to be a great relief, especially since it coincided with lived experiences within her family. She states:

Well, my grandfather probably also had Crohn's disease. He was in hospital 100,000 times because of intestinal obstructions and of his four children, three of them had a chronic inflammatory bowel disease [. . .]. So my aunt died of it during the war at the age of 19. She quite simply starved to death. [2] And my [1] father died after an operation on an abscess. It wasn't yet fully diagnosed, but he had an abscess in his bowel and he died after the operation and it's very likely that that



was also something similar [. . .].⁵⁴ Well, since I'd somehow been thinking for over 30 years that the predisposition is inherited, it [the genetic explanation of some aspects of chronic inflammatory bowel disease] wasn't particularly sensational for me. Well, I just accepted it. [2] [. . .] But I think it was a relief. It was a relief to know. Above all [1], because of this psychosomatic theory, I mean, for many people this is a 'my-fault theory' of the type, 'You just have to try hard enough and you'll be well again.' I mean, that's actually not very funny.⁵⁵

Two aspects of these statements are particularly interesting. First, Agathe has pre-existing genealogical inheritance ideas, which in her eyes are only confirmed by the scientific molecular biological evidence. In other words, she creates her own concept of intrafamilial disease transmission (her own genome 2) and takes it as relevant experiential knowledge before genome 1 (the scientific and biomedical concept) became important in the explanation of chronic inflammatory bowel disease in her life. Secondly, Agathe's statements exemplify something that is characteristic for all participants in our study who interpret their disease experience in the context of guilt narratives. She welcomes the rise of genetic explanations and instrumentalises them as a kind of tool with which to rebut the perceptions of the disease in her social environment. Through this, genes gain lifeworld significance as a defence against the attribution of irresponsibility (and individual guilt feelings resulting from this) by their relatives, friends, colleagues and so on.⁵⁶

Narrative 2: Agency

Other participants interpret the geneticisation of chronic inflammatory bowel diseases through a complementary narrative – mostly against the background of a social environment that turns more towards lived experience. Although they also experience occasional guilt about the impact of the disease on their relatives, they manage to use it positively by converting it into agency. This works particularly when they receive positive feedback or prove to be resilient against guilt narratives.⁵⁷ These participants prefer psychosomatic explanations over genetic models because they assume that they can deal with them more autonomously: a kind of agency that, in their eyes, is lost with genetic models.

A good example of this was provided by 45-year-old Sabine. In her view, self-responsibility is the key to living well while coping with chronic inflammatory bowel disease, and the best way to achieve this is through various methods of psychotherapeutic treatment plus self-care. From the perspective of some affected persons like Sabine, genetic explanations threaten this because, in her view, the genetic explanation makes it easy for patients and their relatives to diffuse responsibility. Sabine explains:

I think general personal responsibility gets a *very* raw deal, and um, if our musicians [the scientists and doctors who advocate genetic explanations for chronic inflammatory bowel disease] now start to sing its praises, um, then I'm, that's my



fault alone. So I would agree that, it's perhaps ignorance, it's definitely terribly frightening to say all at once that there's something physically wrong and I'm responsible for it myself.⁵⁸

Against this background, the disease can be interpreted as a compass for or a companion in self-care. In the words of Sabine: 'I am, um, very much convinced that Crohn's is my buddy, that he's saying inside me: "Now look, you've gone too far here." Or, "Hey, won't you even stop?"'⁵⁹

Sabine describes a way of dealing positively with the disease. But this agency is also interpreted as fragile and is threatened by genetic explanations, particularly through the associated risk of loss of personal responsibility.

The two narratives presented above should give a brief impression of the complex exploration of genomic explanations through the eyes of concerned persons and their social environment. They show how deeply scientific explanations and their interpretations can be interwoven with lifeworld experiences and their respective epistemologies: genetic probabilities get interlaced with individual feelings about guilt or shame; genetic explanatory models become conceptualised as a protective shield against blame from the patient's environment and so on. They also show that the interpretations of genetic information in genome 2 cannot be separated from illness narratives and concrete disease experiences. The narratives of Ulrike, Ute, Mechthild, Agathe, Sabine and other participants in our study indicate that patients produce a certain kind of knowledge, which must be seen and integrated as a relevant element for the conceptualisation of medico-scientific concepts.

Conclusion

Genomics is about human bodies, both lived bodies and bodies conceptualised by the life sciences. Those who are not professional geneticists are lay people with regard to scientific genomic knowledge. The lay side is nevertheless very active in interpreting and making sense of genomic information. Lay people are experts in their reflexive embodiment, which is interpretative work on their lived body. To study the genome as it appears in lifeworld contexts means to appreciate patients' and families' knowledge of the diseases. It contributes to a fuller understanding of the essence of genomic information. Reflexive embodiment of genomics is not a scientific but a cultural project. To understand genomic information is a real translation (not at all an application or just a simplified explanation) of information in biomedical frameworks into information in the meaningful frameworks of individual and social lives.

Acknowledgements

We are grateful to Sarah Atkinson, Monica Buckland, Jackie Leach Scully and Angela Woods for helpful comments on earlier versions of the manuscript and to Monica Buckland for language revision.



Further Reading

- Robert P. George, 'Ethics, Politics, and Genetic Knowledge', *Social Research* 73 (2006), pp. 1029–32.
- Robert L. Klitzman, *Am I My Genes? Confronting Fate and Family Secrets in the Age of Genetic Testing* (Oxford: Oxford University Press, 2012).
- Monica Konrad, *Narrating the New Predictive Genetics: Ethics, Ethnography and Science* (Cambridge: Cambridge University Press, 2005).
- Martin Richards, 'Reading the Runes of My Genome: A Personal Exploration of Retail Genetics', *New Genetics and Society* 29 (2010), pp. 291–310.
- Jackie Leach Scully, Rouven Porz and Christoph Rehm-Sutter, "'You Don't Make Genetic Test Decisions from One Day to the Next'" – Using Time to Preserve Moral Space', *Bioethics* 21 (2007), pp. 208–17.

Notes

1. Rayna Rapp, *Testing Women, Testing the Fetus: The Social Impact of Amniocentesis in America* (New York: Routledge, 1999), p. 3.
2. Monica Konrad, *Narrating the New Predictive Genetics: Ethics, Ethnography and Science* (Cambridge: Cambridge University Press, 2005).
3. Martin Richards, 'Reading the Runes of My Genome: A Personal Exploration of Retail Genetics', *New Genetics and Society* 29 (2010), pp. 291–310.
4. Maurice Merleau-Ponty, *Phénoménologie de la perception* (Paris: Gallimard, 1945), pp. 114ff. (First Part, §10).
5. Shaun Gallagher, 'Body Image and Body Schema: A Conceptual Clarification', *Journal of Mind and Behavior* 7.4 (1986), pp. 541–54.
6. Karin Knorr Cetina, 'Culture in Global Knowledge Societies: Knowledge Cultures and Epistemic Cultures', *Interdisciplinary Science Reviews* 32.4 (2013).
7. Kristien Hens, Wybo Dondorp, Alan H. Handyside, Joyce Harper, Ainsley J. Newson, Guido Pennings, Christoph Rehm-Sutter and Guido de Wert, 'Dynamics and Ethics of Comprehensive Preimplantation Genetic Testing: A Review of the Challenges', *Human Reproduction Update* 19 (2013), pp. 366–75.
8. Bernard Dickens, 'Ethical and Legal Aspects of Noninvasive Prenatal Genetic Diagnosis', *International Journal of Gynecology & Obstetrics* 124 (2014), pp. 181–4.
9. William Viney, 'Getting the Measure of Twins', in this volume, pp. XX–XX; Effy Vayena and Barbara Prainsack, 'Regulating Genomics: Time for a Broader Vision', *Science Translational Medicine* 5 (2013), pp. 2–3; and Barbara Prainsack and Alena Buyx, 'A Solidarity-based Approach to the Governance of Research Biobanks', *Medical Law Review* 21 (2013), pp. 71–91.
10. Jeantine E. Lunshof, George M. Church and Barbara Prainsack, 'Raw Personal Data: Providing Access', *Science* 343 (2014), pp. 373–4; Christoph Rehm-Sutter, 'Pflicht zur Information', in Johann S. Ach, Beate Lüttenberg and Michael Quante (eds), *Wissen.Leben.Ethik: Themen und Positionen der Bioethik* (Münster: Mentis, 2014), pp. 53–65.
11. Robert C. Green, Jonathan S. Berg, Wayne W. Grody, Sarah S. Kalia, Bruce R. Korf, Christa L. Martin, Amy L. McGuire, Robert L. Nussbaum, Julianne M. O'Daniel, Kelly E. Ormond, Heidi L. Rehm, Michael S. Watson, Marc S. Williams and Leslie G. Biesecker,

- ‘ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing’, *Genetics in Medicine* 15.7 (2013), pp. 565–74.
12. Still relevant is the collection edited by Theresa Marteau and Martin Richards, *The Troubled Helix: Social and Psychological Implications of the New Human Genetics* (Cambridge: Cambridge University Press, 1996).
 13. Barbara Prainsack and Jenny Reardon, ‘Misdirected Precaution’, *Nature* 456 (2008), pp. 34–5.
 14. Robert L. Klitzman, *Am I My Genes? Confronting Fate and Family Secrets in the Age of Genetic Testing* (Oxford: Oxford University Press, 2012); Carl F. Cranor (ed.), *Are Genes Us? The Social Consequences of the New Genetics* (New Brunswick, NJ: Rutgers University Press, 1994).
 15. This term was introduced by Nick Crossley in *Reflexive Embodiment in Contemporary Society* (Maidenhead: Open University Press, 2006).
 16. Gale M. Sinatra, Dorothe Kienhues and Barbara K. Hofer, ‘Addressing Challenges to Public Understanding of Science: Epistemic Cognition, Motivated Reasoning and Conceptual Change’, *Educational Psychologist* 49 (2014), pp. 123–38; and Brigitte Nerlich, Richard Elliott and Brendon Larson (eds), *Communicating Biological Sciences: Ethical and Metaphorical Dimensions* (Farnham: Ashgate, 2009).
 17. Robert L. Klitzman (*Am I My Genes?*) studied the local understanding of genetic information about Huntington’s disease, alpha-1 antitrypsin deficiency and breast cancer by interviewing individuals who did and did not have symptoms, and who had and had not had genetic testing.
 18. Ruth R. Faden and Tom L. Beauchamp, *A History and Theory of Informed Consent* (Oxford: Oxford University Press, 1986); and Christoph Rehmann-Sutter, ‘Das ganze Genom: Ethische Überlegungen zur vollständigen Sequenzierung der individuellen “NA”’, in Claus R. Bartram, Monika Bobbert, Dieter Dölling, Thomas Fuchs, Grit Schwarzkopf and Klaus Tanner (eds), *Der (un)durchsichtige Mensch* (Heidelberg: Universitätsverlag, 2012), pp. 255–78.
 19. We refer to the work of social philosophers Margaret S. Archer (2007) and Nick Crossley (2006), who explore how humans develop their identities, aside from classical dualisms. They investigate the internal dialogue about experiences and new bodies of knowledge in the context of everyday practices and the journey through life.
 20. Margaret S. Archer, *Making our Way through the World: Human Reflexivity and Social Mobility* (Cambridge: Cambridge University Press, 2007), pp. 314–25; cf. Nikolas Rose, ‘Molecular Biopolitics, Somatic Ethics and the Spirit of Biocapital’, *Social Theory and Health* 5 (2007), pp. 3–29.
 21. Robert P. George, ‘Ethics, Politics, and Genetic Knowledge’, *Social Research* 73 (2006), pp. 1029–32; cf. Christoph Rehmann-Sutter, ‘Genetics, A Practical Anthropology’, in Marcus Düwell, Christoph Rehmann-Sutter and Dietmar Mieth (eds), *The Contingent Nature of Life: Bioethics and the Limits of Human Existence* (Dordrecht: Springer, 2008), pp. 37–52.
 22. See Lily E. Kay, *Who Wrote the Book of Life? A History of the Genetic Code* (Stanford: Stanford University Press, 2000).
 23. See Susan Oyama, *The Ontogeny of Information: Developmental Systems and Evolution* (Cambridge: Cambridge University Press, 1986); Eva M. Neumann-Held and Christoph Rehmann-Sutter (eds), *Genes in Development: Re-Reading the Molecular Paradigm* (Durham, NC: Duke University Press, 2006); and Kirsten Schmidt, *Was sind Gene nicht? Über die Grenzen des biologischen Essentialismus* (Bielefeld: Transcript, 2014).

24. Cf. the 'subject body' and the 'object body' in P. Ricœur, *Freedom and Nature: The Voluntary and the Involuntary*, trans. E. V. Kohák (Evanston: Northwestern University Press, 1966), p. 10.
25. Edmund Husserl, *Die Krisis der europäischen Wissenschaften und die transzendente Phänomenologie*, ed. by E. Ströker (Hamburg: Meiner, 2012).
26. Alfred Schütz and Thomas Luckmann, *Strukturen der Lebenswelt*, 2 vols (Frankfurt am Main: Suhrkamp, 1979 and 1984).
27. Felicity Callard, Diana Rose, Emma-Louse Hanif, Jody Quigley, Kathryn Greenwood and Til Wykes, 'Holding Blame at Bay? "Gene Talk" in Family Members' Accounts of Schizophrenia Aetiology', *BioSocieties* 7 (2012), pp. 273–93.
28. The contrast of two 'gazes' refers to Blumenberg's 'Lebenswelt und Technisierung unter Aspekten der Phänomenologie' in his *Wirklichkeiten in denen wir leben* (Stuttgart: Reclam, 1981), pp. 7–54.
29. Abby Lippman, 'Prenatal Genetic Testing and Screening: Constructing Needs and Reinforcing Inequalities', *American Journal of Law and Medicine* 17 (1991), p. 19.
30. Konrad, *Narrating the New Predictive Genetics*.
31. Jackie Leach Scully, Rouven Porz and Christoph Rehmann-Sutter, "'You Don't Make Genetic Test Decisions from One Day to the Next" – Using Time to Preserve Moral Space', *Bioethics* 21 (2007), pp. 208–17.
32. Britta Pelters, *Doing Health in der Gemeinschaft. Brustkrebsgene zwischen gesellschaftlicher, familiärer und individueller Gesundheitsnorm* (Bielefeld: Transcript, 2012).
33. Richards, *Reading the Runes*.
34. Klitzman, *Am I My Genes?*
35. Andrea zur Nieden, *Zum Subjekt der Gene werden: Subjektivierungsweisen im Zeichen der Genetisierung von Brustkrebs* (Bielefeld: Transcript, 2013).
36. Cf. Juliet Corbin and Anselm Strauss, 'Grounded Theory Research: Procedures, Canons, and Evaluative Criteria', *Qualitative Sociology* 13 (1990), pp. 3–21; Kathy C. Charmaz, "'Discovering" Chronic Illness: Using Grounded Theory', *Sociology of Science and Medicine* 30 (1990), pp. 1161–72; and Kathy C. Charmaz, *Constructing Grounded Theory: A Practical Guide through Qualitative Analysis* (Thousand Oaks: Sage Publications, 2006).
37. Elizabeth Chapman and Jonathan A. Smith, 'Interpretative Phenomenological Analysis and the New Genetics', *Journal of Health Psychology* 7.2 (2002), pp. 125–30; Jonathan A. Smith and Michael Osborn, 'Interpretative Phenomenological Analysis', in Jonathan A. Smith (ed.), *Qualitative Psychology: A Practical Guide to Research Methods* (Thousand Oaks: Sage Publications, 2003), pp. 53–80; Jonathan A. Smith, Paul Flowers and Michael Larkin, *Interpretative Phenomenological Analysis: Theory, Method and Research* (Thousand Oaks: Sage Publications, 2009); Elizabeth Cassidy, Frances Reynolds, Sandra Naylor and Lorraine De Souza, 'Using Interpretative Phenomenological Analysis to Inform Physiotherapy Practice: An Introduction with Reference to the Lived Experience of Cerebellar Ataxia', *Physiotherapy Theory and Practice* 27 (2011), pp. 263–77.
38. Smith and Osborn, *Interpretative Phenomenological Analysis*, p. 53.
39. Dana Mahr, 'Matthias Flacius Illyricus (1520-1575). Eine erste Theorie der Hermeneutik im Zeitalter der Reformation', in Susanne Luther and Ruben Zimmermann (eds), *Studienbuch Hermeneutik. Bibelauslegung durch die Jahrhunderte als Lernfeld der Textinterpretation. Portraits – Modelle – Quellentexte* (Gütersloh: Gütersloher Verlagshaus, 2014), pp. 158–65.
40. Smith and Osborn, *Interpretative Phenomenological Analysis*, p. 53.

41. See our project homepage: <<http://www.imgwf.uni-luebeck.de/livedgenome/introduction.html>> (accessed 13 April 2015).
42. This conspicuous gender distribution will be a subject at a later stage of our project.
43. Anonymous, 'A Patient's Perspective: My Battle with Crohn's Disease', *American Journal of Gastroenterology* 102 (2007), pp. 482.
44. Interview with Nina and Jens.
45. All interview passages quoted were translated from German into English. We have tried to preserve the linguistic style of the participants as far as possible. Square brackets tagged with ellipsis indicate omitted content that is not relevant for the argumentation of this chapter. Ellipsis without square brackets indicates that the interview partner paused her or his story at this point for more than 1 second. Square brackets also sometimes contain explanatory comments by the authors.
46. Interview with the participant Ulrike. Timestamp: 00:17:40–1.
47. To counter such attributions and accusations, some participants report that they come up with excuses for their condition, absence or delay. See, for example: Interview with the participating couple Hendrik and Melanie. Timestamp: 00:16:32–8.
48. Typically, 34-year-old Linda was told here: 'It's clear you're just doing too much!' See, for example: Interview with the participant Linda. Timestamp: 01:16:16–3.
49. Interview with the participant Ute. Timestamp: 00:22:48–7.
50. Interview with the participant Mechthild. Timestamp: 00:54:55–3.
51. Interview with the participant Agathe. Timestamp: 00:13:20.
52. Ibid. Timestamp: 00:13:20.
53. Ibid. Timestamp: 00:18:15.
54. Ibid. Timestamp: 00:21:46.
55. Ibid. Timestamp: 00:34:34.
56. Interview with the participant Ute. Timestamp: 00:22:00–0.
57. Cf. Interview with the participant Sabine.
58. Interview with the participant Sabine. Timestamp: 00:28:53.
59. Ibid. Timestamp: 00:18:07.